NasdaqGM - Nasdaq Real Time Price USD

Incannex Healthcare Inc. (IXHL)

0.1867
+0.0017
+(0.92%)
As of 11:49:04 AM EDT. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for IXHL

Recent News: IXHL

View More
Incannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program

Incannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program
GlobeNewswire 2 days ago
Incannex Healthcare Inc. Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol Clearance

Incannex Healthcare Inc. Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol Clearance
GlobeNewswire 7 days ago
Incannex Healthcare Inc. Enters Agreement to Cancel Remaining Series A Warrants, Eliminating Up to 347.2 Million Shares from Potential Dilution Ahead of IHL-42X Phase 2 Topline Results

Incannex Healthcare Inc. Enters Agreement to Cancel Remaining Series A Warrants, Eliminating Up to 347.2 Million Shares from Potential Dilution Ahead of IHL-42X Phase 2 Topline Results
GlobeNewswire 8 days ago
Incannex Healthcare Inc. Executes Strategic Cancellation of 50.4% of Series A Warrants, Significantly Reducing Potential Dilution

Incannex Healthcare Inc. Executes Strategic Cancellation of 50.4% of Series A Warrants, Significantly Reducing Potential Dilution
GlobeNewswire 16 days ago
Incannex Announces Potential Reduction of Up to 50.4% of its Series A Warrants

Incannex Announces Potential Reduction of Up to 50.4% of its Series A Warrants
GlobeNewswire 20 days ago
Incannex Healthcare Inc. Reports Fiscal Third Quarter 2025 Financial Results and Business Updates

Incannex Healthcare Inc. Reports Fiscal Third Quarter 2025 Financial Results and Business Updates
GlobeNewswire 21 days ago
Incannex Healthcare Inc. Provides Clinical Program Update on IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)

Incannex Healthcare Inc. Provides Clinical Program Update on IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)
GlobeNewswire 22 days ago
Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)

Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)
GlobeNewswire 2 months ago
Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules

Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules
GlobeNewswire 2 months ago
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2025

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2025
Newsfile 3 months ago
Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates

Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates
GlobeNewswire 3 months ago
View More

Related Tickers

INM InMed Pharmaceuticals Inc.
3.3894
+13.74%
 
IMCC IM Cannabis Corp.
2.8650
+4.18%
 
PTPI Petros Pharmaceuticals, Inc.
0.0300
-1.64%
 
SHPH Shuttle Pharmaceuticals Holdings, Inc.
0.1776
-3.90%
 
UPC Universe Pharmaceuticals INC
4.1500
-1.66%
 
SXTC China SXT Pharmaceuticals, Inc.
1.3798
+5.33%
 
RGC Regencell Bioscience Holdings Limited
602.01
-3.06%
 
IRWD Ironwood Pharmaceuticals, Inc.
0.5763
-4.29%
 
QNTM Quantum BioPharma Ltd.
13.85
-4.68%
 
SCYX SCYNEXIS, Inc.
0.9151
-2.55%